Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment

Subjects with HIV who have viral suppression on current regimen but also have side effects/intolerance will change their current regimen to a combination of Raltegravir and Atazanavir and

raltegravir
hysterectomy
antiretroviral agents
antiviral drugs
atazanavir
  • 8 views
  • 07 Nov, 2020
  • 1 location
HIV Antiretroviral Drugs and Metabolism

will be studied before and at the end of four weeks of taking ritonavir, lopinavir/ritonavir or atazanavir/ritonavir. Hypothesis 2: NNRTI drugs do not increase HDL by increasing apo AI

antiretroviral agents
lopinavir
efavirenz
atazanavir
ritonavir
  • 6 views
  • 07 Nov, 2020
  • 1 location
Antiviral Agents Against COVID-19 Infection

damage that follows this phase. The clinically approved substances considered for this study are used for treatment of other virus diseases, like HIV (atazanavir) and HCV (sofosbuvir and daclatasvir

  • 0 views
  • 04 Jun, 2021
  • 1 location
Study Evaluating Pharmacokinetics (PK) Safety and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Virologically Suppressed Pediatric Participants

Cohort 1: The primary objectives are: To evaluate the steady-state pharmacokinetics (PK) of Atazanavir (ATV) and Darunavir (DRV) and confirm the dose of Cobicistat-boosted

antiretroviral
emtricitabine
tenofovir
cobicistat
emtricitabine/tenofovir
  • 236 views
  • 18 Jun, 2021
  • 41 locations
HIV-1 Infected Patients Phase II Trial Dual Combination Doravirine/Raltegravir Open Label

The objective of antiretroviral therapy (ART) is the maintenance of HIV viral suppression, the optimal condition to prevent disease progression, to optimize immune restoration, to prevent the development of viral resistance and to reduce viral transmission. Antiretroviral therapy has to be maintained long life over decades in the absence of …

  • 0 views
  • 12 Feb, 2021
  • 1 location
Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP )

This is a prospective multicenter cohort study. The question arises as to whether treatment with protease inhibitors (PIs) could have a preventive role for COVID-19 infection, especially since patients living with HIV (PLWHIV) have not been described as more at risk of developing COVID-19 infection. The aim of our study …

  • 0 views
  • 25 Jan, 2021
  • 5 locations
Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD

medication that contains a boosted protease inhibitor (PI) drug (such as Lopinavir or Atazanavir) (Group 2). People taking TLD and receiving medication for TB that includes the drug rifampicin (RIF

  • 5 views
  • 25 Jan, 2021
  • 14 locations
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Due to the potential for pregnancy-induced changes in the pharmacokinetics of medication, one cannot assume that the currently licensed doses of the medication to be tested under this protocol lead to adequate exposure in an HIV-infected pregnant woman. For the agents under study no or limited pharmacokinetic data during pregnancy …

antiretroviral
hiv antibodies
antibody test
haart
hiv antibody
  • 156 views
  • 25 Mar, 2021
  • 25 locations
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.

The purpose of the Antiretroviral Pregnancy Registry (Registry) is to detect any major teratogenic effect involving any of the Registry drugs when administered to pregnant women. Registration is voluntary and confidential with information obtained from the health care provider. A Registry-assigned identifier allows for follow-up capability. Information on subjects is …

antiretrovirals
antiretroviral
prenatal
hepatitis
antiretroviral agents
  • 66 views
  • 25 Jan, 2021
  • 1 location
A Long-term Follow-up of the HIV-NAT Cohort

With HIV/AIDS increasingly considered a chronic disease, 24-, or 48-week data from antiretroviral studies are no longer sufficient. Only with long-term follow-up and outcome data will shed some much-needed light on the answers of questions that have stumped us for several years. Data from a large observational cohort of patients …

antiretroviral
antiretroviral agents
antiretroviral therapy
hiv viral load
AIDS
  • 2 views
  • 25 Jan, 2021
  • 1 location